ASRT2
MCID: AST056
MIFTS: 30

Asthma-Related Traits 2 (ASRT2)

Categories: Genetic diseases, Immune diseases, Skin diseases

Aliases & Classifications for Asthma-Related Traits 2

MalaCards integrated aliases for Asthma-Related Traits 2:

Name: Asthma-Related Traits 2 56 73
Asthma-Related Traits, Susceptibility to, 2 56 29 6 71
Asthma, Susceptibility to, 2 56 13
Asrt2 56 73
Asthma-Related Traits, Susceptibility to, Type 2 39
Asthma 2 56

Classifications:



External Ids:

OMIM 56 608584
MeSH 43 D001249
MedGen 41 C1837811
UMLS 71 C1837811

Summaries for Asthma-Related Traits 2

OMIM : 56 Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, and dyspnea; bronchial hyperresponsiveness (BHR) as assessed by methacholine challenge test; serum IgE levels; atopy; and atopic dermatitis (Laitinen et al., 2001; Illig and Wjst, 2002). For a general phenotypic description and a discussion of genetic heterogeneity of asthma, see 600807. (608584)

MalaCards based summary : Asthma-Related Traits 2, also known as asthma-related traits, susceptibility to, 2, is related to asthma and respiratory failure. An important gene associated with Asthma-Related Traits 2 is NPSR1 (Neuropeptide S Receptor 1). The drugs Omalizumab and Sotalol have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and heart.

UniProtKB/Swiss-Prot : 73 Asthma-related traits 2: Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, dyspnea, bronchial hyperresponsiveness as assessed by methacholine challenge test, serum IgE levels, atopy and atopic dermatitis.

Related Diseases for Asthma-Related Traits 2

Diseases in the Asthma-Related Traits 2 family:

Asthma-Related Traits 1 Asthma-Related Traits 3
Asthma-Related Traits 4 Asthma-Related Traits 5
Asthma-Related Traits 6 Asthma-Related Traits 7
Asthma-Related Traits 8

Diseases related to Asthma-Related Traits 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 asthma 10.1
2 respiratory failure 9.7
3 allergic hypersensitivity disease 9.7
4 pneumonia 9.7
5 eosinophilic pneumonia 9.7
6 chronic eosinophilic pneumonia 9.7

Graphical network of the top 20 diseases related to Asthma-Related Traits 2:



Diseases related to Asthma-Related Traits 2

Symptoms & Phenotypes for Asthma-Related Traits 2

Clinical features from OMIM:

608584

Drugs & Therapeutics for Asthma-Related Traits 2

Drugs for Asthma-Related Traits 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
3
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
4
Budesonide Approved Phase 4 51333-22-3 63006 5281004
5
Montelukast Approved Phase 4 158966-92-8 5281040
6
Ciclesonide Approved, Investigational Phase 4 141845-82-1, 126544-47-6 444033
7
Theophylline Approved Phase 4 58-55-9 2153
8
Beclomethasone Phase 4 4419-39-0 20469
9 Vaccines Phase 4
10 Formoterol Fumarate Phase 4
11 Adrenergic beta-Antagonists Phase 4
12 Sodium Channel Blockers Phase 4
13 Adrenergic Antagonists Phase 4
14 Sympatholytics Phase 4
15 Anti-Arrhythmia Agents Phase 4
16 Diuretics, Potassium Sparing Phase 4
17 Respiratory System Agents Phase 4
18 Hormones Phase 4
19 Anti-Asthmatic Agents Phase 4
20 glucocorticoids Phase 4
21 Hormone Antagonists Phase 4
22 Anti-Inflammatory Agents Phase 4
23 Bronchodilator Agents Phase 4
24 Neurotransmitter Agents Phase 4
25 Adrenergic beta-Agonists Phase 4
26 Adrenergic Agents Phase 4
27 Adrenergic Agonists Phase 4
28 Leukotriene Antagonists Phase 4
29
Salmeterol xinafoate Phase 4 94749-08-3 56801
30 Phosphodiesterase Inhibitors Phase 4
31 Vasodilator Agents Phase 4
32
Nicotine Approved Phase 3 54-11-5 942 89594
33
Carbon monoxide Approved, Investigational Phase 3 630-08-0 281
34 Parasympatholytics Phase 3
35 Cholinergic Agents Phase 3
36 Pharmaceutical Solutions Phase 3
37 Cholinergic Antagonists Phase 3
38 Tiotropium Bromide Phase 3 136310-93-5
39 Bromides Phase 3
40
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
41
Hydroxocobalamin Approved Phase 2 13422-51-0 15589840 11953898
42
Terbutaline Approved Phase 2 23031-25-6 5403
43
Cyanocobalamin Approved, Nutraceutical Phase 2 68-19-9 44176380
44
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
45
Cobalamin Experimental Phase 2 13408-78-1 6857388
46
Quercetin Experimental, Investigational Phase 2 117-39-5 5280343
47 Vitamins Phase 2
48 Vitamin B 12 Phase 2
49 Vitamin B12 Phase 2
50 Tocolytic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 mRNA Expression as a Biomarker of Xolair (Omalizumab) Response Unknown status NCT01584687 Phase 4
2 A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma Completed NCT01520688 Phase 4 Fluticasone, Budesonide, Beclomethasone;Fluticasone, Beclomethasone, Budesonide;Budesonide, Fluticasone, Beclomethasone;Budesonide, Beclomethasone, Fluticasone;Beclomethasone, Fluticasone, Budesonide;Beclomethasone, Budesonide, Fluticasone
3 Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4) Completed NCT02967393 Phase 4 ccIIV4;IIV4
4 Randomised Controlled Single and Chronic Dosing Crossover Comparison of Extra Fine Particle Formoterol and Coarse Particle Salmeterol in Asthmatic Patients With Persistent Small Airways Dysfunction Completed NCT01892787 Phase 4 Formoterol;Salmeterol
5 Open Randomized Low Interventional Clinical Trial to Compare Efficiency in Control Symptoms Between Fluticasone Propionate/Formoterol K-haler (Medium Strength) vs High Strength ICS/LABA in the Treatment of Patients With Persistent Asthma Not yet recruiting NCT04271839 Phase 4
6 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
7 The Temporal Sequence of Inflammatory Mediators During a Controlled Exacerbation of Asthma by Steroid Withdrawal. Terminated NCT00395239 Phase 4 inhaled corticosteroid
8 Feasibility of a Personalised Medicine Clinic for Children With Asthma Aged 5-11 Years Terminated NCT03269318 Phase 4 Montelukast or Salmeterol or Theophylline or Steroid
9 A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Children (6 to 11 Years Old) With Severe Persistent Asthma Completed NCT01634152 Phase 3 Placebo;Tiotropium low dose mcg;Tiotropium high dose
10 A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma Completed NCT01634139 Phase 3 Tiotropium low dose QD;Tiotropium high dose QD;Placebo
11 A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma Completed NCT01277523 Phase 3 tiotropium high dose;placebo;tiotropium low dose
12 Sustaining Cessation in Smokers With Kids With Asthma Completed NCT00862368 Phase 3
13 A 12-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids Withdrawn NCT01026870 Phase 3 SCH 32088 mometasone furoate (MF) metered-dose inhaler;Placebo metered-dose inhaler BID
14 Orthomolecular Treatment as add-on Therapy for Childhood Asthma Unknown status NCT00672529 Phase 2
15 A Double-blind, Randomised, Incomplete Block, Crossover, Placebo-controlled, Dose-response Study to Assess Bronchial Hyperresponsiveness and Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adult Subjects With Mild to Moderate Asthma Completed NCT00995800 Phase 2 Fluticasone propionate / Formoterol fumarate
16 A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol "As-needed", or Terbutaline "As-needed" or Regular Use of Budesonide + Terbutaline "As-needed", in Patients With Mild Intermittent Asthma Completed NCT00989833 Phase 2 budesonide;terbutaline;budesonide/formoterol
17 A Randomised, Double- Blind, 2 Way Cross-over Study to Determine 24-hour FEV1-time Profile of Inhaled Tiotropium, Delivered Via the Respimat Inhaler, After 4 Weeks of Once Daily [5 mcg in the Evening (2 Actuations of 2.5 mcg)] or Twice Daily [2.5 mcg in the Morning and Evening (2 Actuations of 1.25 mcg)] Administration in Patients With Moderate Persistent Asthma. Completed NCT01696071 Phase 2 Tiotropium 5 mcg qd;Tiotropium 2.5 mcg bid
18 Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma Completed NCT01393340 Phase 2 Omalizumab;Placebo
19 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 45.5, 90.9 and 181.8 mcg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA 220 mcg b.i.d. in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy Terminated NCT01397201 Phase 2 Placebo;BI 54903;Placebo;Placebo;Fluticasone;BI 54903;BI 54903;Placebo;Placebo;Placebo
20 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 22.7, 45.5 and 90.9 Doses b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA MDI 88 mcg b.i.d. in Patients With Asthma Inadequately Controlled on SABA Therapy Terminated NCT01397162 Phase 2 Fluticasone propionate;Placebo;Placebo;BI 54903;BI 54903;Placebo;Placebo;Placebo;Placebo;BI 54903
21 A Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 90.9, 181.8 and 363.6 µg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA MDI 440 µg b.i.d. in Patients With Asthma Inadequately Controlled on Medium Dose ICS Therapy Terminated NCT01396278 Phase 2 Placebo;Placebo;Fluticasone propionate;BI 54903;Fluticasone propionate;Placebo;BI 54903;BI 54903;Placebo;Placebo
22 A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of a 12-week Treatment With BI 54903 at Doses of 181.8 Mcg b.i.d. and 363.6 Mcg q.d. (p.m. Dosing) Administered Via Respimat® Inhaler in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy Withdrawn NCT01458912 Phase 2 Placebo matching Respimat;Placebo matching Respimat;BI 54903 MD;BI 54903 HD
23 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study Assessing Efficacy and Safety of a 12 Week Treatment With BI 54903 Administered at 90.9 Mcg b.i.d. and 181.8 Mcg q.d. (p.m.Dosing) Via Respimat® Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone Withdrawn NCT01458886 Phase 2 BI 54903 MD;Placebo matching Respimat;Placebo matching Respimat;BI 54903
24 Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2 Unknown status NCT01224951 Beclomethasone
25 Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of Psoriasis Unknown status NCT00372580
26 Changes in the Lung Clearance Index as Measured by Multiple-breath Washout, in Pediatric Patients With Asthma After Challenge With Inhaled Steroids and Short-acting Bronchodilator Unknown status NCT02678949 Inhaled Fluticasone 50 mcg/twice day;Inhaled Fluticasone 100 mcg/twice day;Inhaled Albuterol
27 Influence of Propofol on Alveolar Macrophage Immunity in Asthmatic Patients Undergoing General Anesthesia Completed NCT00676416 2,6-Diisopropylphenol
28 p38 MAPK Activation as the Basis for Corticosteroid Insensitivity in Severe Asthma Completed NCT00676572
29 Study of T-Regulatory Cells in Asthma Completed NCT02574351
30 Redox Determinants of Severe Asthma: A Substudy of the NHLBI Severe Asthma Research Program Completed NCT00590005
31 Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma Completed NCT01690793
32 Randomized Controlled Trial of Marine Lipid Fraction PCSO-524™ on Airway Inflammation and Hyperpnea-Induced Bronchoconstriction in Asthma Completed NCT01504646
33 Improving Pediatric Asthma Care Through Inhaled Steroids in Schools (ISIS) Completed NCT01891773
34 Peer-Assisted Asthma Self-Management Program for Adolescents Completed NCT01161225
35 A Pilot Stress Management Intervention for High Risk Children With Asthma Completed NCT02091648
36 Multiplex Molecular Detection of Respiratory Pathogens of Adult Patients Admitted to Hospital for Exacerbation of Asthma and Chronic Obstructive Pulmonary Disease and Their Clinical Outcomes. Completed NCT02866357
37 Longitudinal Study of Asthma From Birth to Adulthood Completed NCT00005475
38 Using MEDUCATION to Improve Asthma Medication Device Technique Completed NCT01641211
39 Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma Completed NCT02703467
40 RESynchronizaTiOn theRapy and bEta-blocker Titration : RESTORE Completed NCT02173028
41 The Efficacy of Written Treatment Plans in Asthma Completed NCT00149461
42 Comparison of Pulmonary Complications Related to Laparoscopic Sleeve Gastrectomy and Laparoscopic Adjustable Gastric Banding Completed NCT01178567
43 Improving Care for Minority Children With Asthma: Professional Education in Public Health Clinics Completed NCT00005713
44 Epidemiology of Symptom Perception in Childhood Asthma Completed NCT00005461
45 iTRACC (Improving Technology-Assisted Recording of Asthma Control in Children) Completed NCT02994238
46 AsthmaVent - Effect of Mechanical Ventilation on Asthma Control in Children Completed NCT02068573
47 Effects of Green Tea Extract (GTE) on Systemic Oxidative and Antioxidative Status in Chinese Patients With Stable Asthma Completed NCT01187147
48 Follow up of Ventilatory Function in Infant After One (or More) Bronchiolitis During the First Year of Life. Course Towards Asthma Completed NCT00676351
49 Effects of Educational Intervention on Long-Term Outcomes of Hospitalized Children With Asthma Completed NCT01447459
50 National Health Survey of Gulf War Era Veterans and Their Families - Phase III Physical Examinations Completed NCT00032461

Search NIH Clinical Center for Asthma-Related Traits 2

Genetic Tests for Asthma-Related Traits 2

Genetic tests related to Asthma-Related Traits 2:

# Genetic test Affiliating Genes
1 Asthma-Related Traits, Susceptibility to, 2 29 NPSR1

Anatomical Context for Asthma-Related Traits 2

MalaCards organs/tissues related to Asthma-Related Traits 2:

40
Testes, Lung, Heart, Monocytes, T Cells, B Cells, Trachea

Publications for Asthma-Related Traits 2

Articles related to Asthma-Related Traits 2:

(show top 50) (show all 321)
# Title Authors PMID Year
1
Characterization of a common susceptibility locus for asthma-related traits. 56 6
15073379 2004
2
The protective effect of farm animal exposure on childhood allergy is modified by NPSR1 polymorphisms. 56
18285428 2009
3
Biological and genetic interaction between tenascin C and neuropeptide S receptor 1 in allergic diseases. 56
18305139 2008
4
Physical map of an asthma susceptibility locus in 7p15-p14 and an association study of TCRG. 56
12357338 2002
5
Genetics of asthma and related phenotypes. 56
12065182 2002
6
A susceptibility locus for asthma-related traits on chromosome 7 revealed by genome-wide scan in a founder population. 56
11326283 2001
7
Importance of genetic factors in adolescent asthma: a population-based twin-family study. 56
9563721 1998
8
Breathing pattern disorders (dysfunctional breathing) characteristics and outcomes of children and young people attending a secondary care respiratory clinic. 61
32449843 2020
9
Blockade of RANKL/RANK and NF-ĸB signalling pathways as novel therapeutic strategies for allergic asthma: A comparative study in a mouse model of allergic airway inflammation. 61
32339516 2020
10
Building Bridges for Asthma Care Program: A School-Centered Program Connecting Schools, Families, and Community Health-Care Providers. 61
30336726 2020
11
How does the EQ-5D-5L perform in asthma patients compared with an asthma-specific quality of life questionnaire? 61
32534568 2020
12
Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. 61
32245768 2020
13
The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach. 61
31541763 2020
14
Impact of the Choosing Wisely® Campaign Recommendations for Hospitalized Children on Clinical Practice: Trends from 2008 to 2017. 61
31532743 2020
15
Temporary and permanent unfitness of occupational divers. Brest Cohort 2002-2019 from the French National Network for Occupational Disease Vigilance and Prevention (RNV3P). 61
32212151 2020
16
Potentially (near) fatal asthma. 61
31690380 2019
17
Responsive Asthma Care for Teens (ReACT): development protocol for an adaptive mobile health intervention for adolescents with asthma. 61
31434777 2019
18
Asthma symptoms, interactive physical play and behavioral and academic outcomes in urban children with persistent asthma. 61
29969924 2019
19
Phenotypes and endotypes of adult asthma: Moving toward precision medicine. 61
31277742 2019
20
[A bibliometric analysis of research on occupational asthma during 1998 to 2017]. 61
31256523 2019
21
Last station in the eosinophilic asthma with chronic rhinosinusitis and/or nasal polyposis march: Eosinophilic asthma with radiological findings associated with blood eosinophilia. 61
29611776 2019
22
Identifying Barriers to Physical Activity Among African American Women with Asthma. 61
31754624 2019
23
Asthma and youth soccer: an investigation into the level of asthma awareness and training among youth soccer coaches. 61
30697089 2019
24
Eosinophilic asthma, according to a blood eosinophil criterion, is associated with disease severity and lack of control among underprivileged urban Brazilians. 61
30509723 2018
25
Effect of indoor air quality on the natural history of asthma in an urban population in Poland. 61
30401330 2018
26
Mechanisms of organophosphorus pesticide toxicity in the context of airway hyperreactivity and asthma. 61
29952220 2018
27
Chinese guidelines for childhood asthma 2016: Major updates, recommendations and key regional data. 61
29227721 2018
28
Reaction products of hexamethylene diisocyanate vapors with "self" molecules in the airways of rabbits exposed via tracheostomy. 61
28489470 2018
29
Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. 61
29174062 2018
30
Parental Perspectives of Barriers to Physical Activity in Urban Schoolchildren With Asthma. 61
29309846 2018
31
Outdoor air pollution, exhaled 8-isoprostane and current asthma in adults: the EGEA study. 61
29618600 2018
32
Prevalence of Asthma, Asthma Attacks, and Emergency Department Visits for Asthma Among Working Adults - National Health Interview Survey, 2011-2016. 61
29621204 2018
33
Excessive gestational weight gain in first trimester is a risk factor for exacerbation of asthma during pregnancy: A prospective study of 1283 pregnancies. 61
28551030 2018
34
Asthma-related lung function, sleep quality, and sleep duration in urban children. 61
28526251 2017
35
Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance. 61
28163029 2017
36
Association Between Migraine and Atopic Diseases in Childhood: A Potential Protective Role of Anti-Allergic Drugs. 61
28160287 2017
37
Understanding discharge communication behaviours in a pediatric emergency care context: a mixed methods observation study protocol. 61
28412951 2017
38
Designing a physical activity intervention for children with asthma: a qualitative study of the views of healthcare professionals, parents and children with asthma. 61
28341689 2017
39
Early life travelling does not increase risk of atopic outcomes until 15 years: results from GINIplus and LISAplus. 61
28122145 2017
40
Identifying biomarkers for asthma diagnosis using targeted metabolomics approaches. 61
27888993 2016
41
[Rating criteria for selection of an inhaler and instructing its use in patients with asthma and COPD]. 61
28024131 2016
42
Agreement between current and active asthma classification methods, Asthma Call-back Survey, 2011-2012. 61
27050506 2016
43
Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy. 61
27788565 2016
44
A REALLY WHEEZY WAY TO SAVE MONEY. 61
27540214 2016
45
Inhaler Technique in Children With Asthma: A Systematic Review. 61
27130811 2016
46
Asthma management in New York City schools: A classroom teacher perspective. 61
27031532 2016
47
Height growth in children with asthma treated with guideline-recommended dosages of fluticasone and electronically assessed adherence. 61
26644401 2016
48
Perception of Exercise-Induced Bronchoconstriction in College Athletes. 61
27006350 2016
49
Enuresis Nocturna in children with asthma: prevalence and associated risk factors. 61
27287763 2016
50
A regional approach to unmet needs in anaphylaxis. 61
27152604 2016

Variations for Asthma-Related Traits 2

ClinVar genetic disease variations for Asthma-Related Traits 2:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NPSR1 NM_207172.2(NPSR1):c.320A>T (p.Asn107Ile)SNV risk factor 2192 rs324981 7:34818113-34818113 7:34778501-34778501

Expression for Asthma-Related Traits 2

Search GEO for disease gene expression data for Asthma-Related Traits 2.

Pathways for Asthma-Related Traits 2

GO Terms for Asthma-Related Traits 2

Sources for Asthma-Related Traits 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....